| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5625079 | Alzheimer's & Dementia | 2012 | 8 Pages |
Abstract
The reduction in MCI-AD and DAT depends on initial screening age, screening frequency, and specificity. When considering population-level impact of screening-treatment, the effect of these parameters on incidence would need to be weighed against the number of individuals screened and treated.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Nicolas M. Furiak, Kristin Kahle-Wrobleski, Christopher Callahan, Timothy M. Klein, Robert W. Klein, Eric R. Siemers,